Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $51.79 USD
Change Today +0.0221 / 0.04%
Volume 45.4K
ANIP On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 12:28 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

ani pharmaceuticals inc (ANIP) Snapshot

Open
$50.99
Previous Close
$51.77
Day High
$53.02
Day Low
$50.25
52 Week High
07/31/15 - $73.54
52 Week Low
10/15/14 - $24.24
Market Cap
593.6M
Average Volume 10 Days
277.2K
EPS TTM
$3.10
Shares Outstanding
11.5M
EX-Date
--
P/E TM
16.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for ANI PHARMACEUTICALS INC (ANIP)

Related News

No related news articles were found.

ani pharmaceuticals inc (ANIP) Related Businessweek News

No Related Businessweek News Found

ani pharmaceuticals inc (ANIP) Details

ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. It manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products. The company’s targeted areas of product development include narcotics, oncolytics, hormones, and steroids, as well as complex formulations, such as extended release and combination products. Its products include Esterified Estrogen with Methyltestosterone tablets for use in treating vasomotor symptoms of menopause; Fluvoxamine Maleate to treat obsessions and compulsions in patients with obsessive-compulsive disorder; Hydrocortisone Enema and Cortenema for the treatment of ulcerative colitis; and Metoclopramide and Reglan for treating gastroesophageal reflux. The company’s products also comprise Opium Tincture to treat diarrhea by slowing the movement of the intestines, and decreasing the number and frequency of bowel movements; Lithobid for treating the manic episodes of bipolar disorder; and Vancocin to treat difficile-associated diarrhea. In addition, it provides contract manufacturing services for various branded and generic companies. The company markets and sells its products through wholesalers, retail market chains, distributors and mail order pharmacies, and hospitals. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

92 Employees
Last Reported Date: 02/23/15

ani pharmaceuticals inc (ANIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $461.5K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $303.1K
Vice President of Operations
Total Annual Compensation: $131.4K
Vice President of New Business Development & ...
Total Annual Compensation: $259.2K
Compensation as of Fiscal Year 2014.

ani pharmaceuticals inc (ANIP) Key Developments

IDT Australia Limited and ANI Pharmaceuticals Inc Enters into Marketing and Distribution Agreement

IDT Australia Ltd. will get ANI Pharmaceuticals Inc. to market and distribute in the US up to 18 of IDT's recently acquired generic pharmaceutical products. Under the agreement ANI makes an upfront payment of $1 million to IDT for exclusive rights to commercialise the products in the US market. Launch milestones of up to a further $1.25 million will also be payable as the products come back on market.

ANI Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Second Half of 2015; Revises Earnings Guidance for the Full Year of 2015

ANI Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net revenues of $19.516 million compared to $6.647 million a year ago. Operating income was $8.414 million compared to loss of $2.460 million a year ago. Income before provision for income taxes was $5.665 million compared to loss of $2.496 million a year ago. Net income was $3.571 million or $0.31 per diluted share compared to loss of $2.363 million or $0.21 per diluted share a year ago. Adjusted non-GAAP EBITDA was $10.858 million compared to $0.226 million a year ago. Adjusted net income was $6.305 million or $0.55 per diluted share. For six months, the company reported net revenues of $38.315 million compared to $17.546 million a year ago. Operating income was $17.981 million compared to $1.035 million a year ago. Income before provision for income taxes was $12.575 million compared to $1.028 million a year ago. Net income was $7.940 million or $0.68 per diluted share compared to $0.996 million or $0.09 per diluted share a year ago. Adjusted non-GAAP EBITDA was $22.320 million compared to $4.470 million a year ago. Adjusted net income was $12.925 million or $1.12 per diluted share. During the six months ended June 30, 2015, the company generated $2.3 million in positive cash flow from operations, which was net of a $5.2 million increase in the inventories. The company provided earnings guidance for the second half of 2015. For the period, the company expects net revenue in the range of $44 million to $46 million, adjusted non-GAAP EBITDA in the range of $26 million to $28 million and adjusted non-GAAP diluted EPS in the range of $1.32 to $1.38. The company revised earnings guidance for the full year of 2015. For the year, the company expects revenues in the range of $82 million to $84 million, adjusted non-GAAP EBITDA in the range of $48 million to $50 million, depreciation and amortization of $5.75 million, total interest expense of $11.2 million, estimated effective tax rate of 37% and adjusted non-GAAP EPS in the range of $2.44 to $2.50 compared to prior guidance of revenue in the range of $80 million to $88 million, adjusted non-GAAP EBITDA in the range of $48.8 million to $53.1 million, depreciation and amortization of $5.5 million, total interest expense of $11.2 million, estimated effective tax rate of 36.8% and adjusted non-GAAP EPS in the range of $2.44 to $2.67.

ANI Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 04, 2015

ANI Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANIP:US $51.79 USD +0.0221

ANIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $293.67 USD -3.77
Glenmark Pharmaceuticals Ltd 1,026 INR -35.80
Lannett Co Inc $54.43 USD -1.38
Mylan NV $47.89 USD +0.47
View Industry Companies
 

Industry Analysis

ANIP

Industry Average

Valuation ANIP Industry Range
Price/Earnings 16.7x
Price/Sales 7.6x
Price/Book 3.9x
Price/Cash Flow 14.4x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANI PHARMACEUTICALS INC, please visit www.anipharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.